Monoclonal antibody for resisting respiratory syncytial virus as well as preparation method and application of monoclonal antibody

By using monoclonal antibodies targeting the RSV pre-F protein, the problem of insufficient neutralizing efficacy and inadequate cross-protection against variants in existing RSV monoclonal antibody drugs has been solved, providing a highly effective and broad-spectrum RSV prevention strategy, which is particularly suitable for infants and high-risk groups.

CN122127453APending Publication Date: 2026-06-02GUANGZHOU NAT LAB
4 Cites 0 Cited by

Patent Information

Application Number
CN202610526056.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-20
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing RSV monoclonal antibody drugs have insufficient neutralizing efficacy, poor epitope conservation, and lack cross-protection against variant strains, making it difficult to effectively prevent and control RSV infection in infants and high-risk groups.

Method used

A monoclonal antibody against respiratory syncytial virus (RSV) was developed, targeting the conserved RSV pre-F protein antigenic epitope. Antigen-specific B lymphocytes were sorted by flow cytometry, and the antibody was amplified and recombined to obtain a monoclonal antibody with high affinity and broad-spectrum protection. The preparation method is simple and cost-controllable.

Benefits of technology

It provides monoclonal antibodies with high and medium activity and broad-spectrum protective efficacy, which can effectively prevent RSV infection, especially for infants and high-risk groups, and is simple to use and cost-effective.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to an anti-respiratory syncytial virus monoclonal antibody as well as a preparation method and application thereof. The monoclonal antibody for resisting the respiratory syncytial virus, provided by the invention, can recognize a specific antigen epitope of pre-F for resisting the respiratory syncytial virus, and the result of the embodiment shows that the monoclonal antibody has very strong affinity with F protein of the respiratory syncytial virus, has relatively high neutralizing efficacy on A-type and B-type respiratory syncytial viruses, and can prevent RSV (Respiratory Syncytial Virus) infection. The medicine for treating the respiratory syncytial virus, provided by the invention, contains the monoclonal antibody for resisting the respiratory syncytial virus, and has a good protection effect on preventing RSV (Respiratory Syncytial Virus) infection. The preparation method of the monoclonal antibody for treating the respiratory syncytial virus, provided by the invention, is controllable in cost and simple to operate.
Need to check novelty before this filing date? Find Prior Art